Dehong Yan

7PUBLICATIONS
17CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 06, 2025
NY-ESO-1 facilitates anoikis resistance and tumor metastasis by hijacking deubiquitinase OTUB1 to stabilize PP1α.

Pengchao Zhang, Jian Cheng, Zhao Liu

|Mar 27, 2025
MDSC checkpoint blockade therapy: a new breakthrough point overcoming immunosuppression in cancer immunotherapy.

Abdulrahman Ibrahim, Nada Mohamady Farouk Abdalsalam, Zihao Liang

|Jan 24, 2025
Blockade of TIPE2-Mediated Ferroptosis of Myeloid-Derived Suppressor Cells Achieves the Full Potential of Combinatory Ferroptosis and Anti-PD-L1 Cancer Immunotherapy.

Hafiza Kashaf Tariq, Zihao Liang, Lawan Rabiu

|Nov 27, 2024
Etomoxir Sodium Salt Promotes Imidazole Ketone Erastin-Induced Myeloid-Derived Suppressor Cell Ferroptosis and Enhances Cancer Therapy.

Nada Mohamady Farouk Abdalsalam, Zihao Liang, Hafiza Kashaf Tariq

|Mar 29, 2023
FERMT1 Is a Prognostic Marker Involved in Immune Infiltration of Pancreatic Adenocarcinoma Correlating with m6A Modification and Necroptosis.

Qian Wu, Jin Li, Pei Wang

|Jul 05, 2022
Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors.

Mengqi Zhang, Lulu Wang, Wan Liu

Pageof 2

Frequent Collaborators

3 joint publications

Xiaochun Wan

2 joint publications

Lawan Rabiu

1 joint publications

Lukman O Afolabi

1 joint publications

Mariam O Afolabi